Mineralocorticoid Receptor Antagonists
"Mineralocorticoid Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.
| Descriptor ID |
D000451
|
| MeSH Number(s) |
D06.347.700 D27.505.696.399.450.600 D27.505.696.560.500.726.249
|
| Concept/Terms |
Mineralocorticoid Receptor Antagonists- Mineralocorticoid Receptor Antagonists
- Antagonists, Mineralocorticoid Receptor
- Receptor Antagonists, Mineralocorticoid
- Mineralocorticoid Antagonists
- Antagonists, Mineralocorticoid
- Aldosterone Receptor Antagonists
- Antagonists, Aldosterone Receptor
- Receptor Antagonists, Aldosterone
|
Below are MeSH descriptors whose meaning is more general than "Mineralocorticoid Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Mineralocorticoid Receptor Antagonists".
This graph shows the total number of publications written about "Mineralocorticoid Receptor Antagonists" by people in this website by year, and whether "Mineralocorticoid Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mineralocorticoid Receptor Antagonists" by people in Profiles.
-
First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting. J Nephrol. 2024 11; 37(8):2223-2232.
-
Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure. Am J Cardiovasc Drugs. 2024 Jul; 24(4):481-504.
-
The national financial burden of guideline directed medical therapy for heart failure patients from 2013 to 2021. Curr Probl Cardiol. 2024 Aug; 49(8):102684.
-
Mortality, Outcomes, Costs, and Use of?Medicines Following a First Heart?Failure?Hospitalization: EVOLUTION HF. JACC Heart Fail. 2023 10; 11(10):1320-1332.
-
Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders? Nephrol Dial Transplant. 2023 05 31; 38(6):1355-1365.
-
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice. J Diabetes Complications. 2023 04; 37(4):108411.
-
Progress in the management of patients with diabetes and chronic kidney disease. Curr Opin Nephrol Hypertens. 2022 09 01; 31(5):456-463.
-
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 10 27; 10:CD007004.
-
Establishing Baseline Metrics of Heart Failure Medication Use in Children: A Collaborative Effort from the ACTION Network. Pediatr Cardiol. 2021 Feb; 42(2):315-323.
-
Association of Changes in Heart?Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. JACC Heart Fail. 2019 07; 7(7):615-625.